Soleus Capital Management’s Immunic IMUX Stock Holding History

Soleus Capital Management’s Portfolio IMUX Stock Details IMUX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$5M	Buy	+450,000	New	+$4.03M	0.2%	65
2025 Q4	–	Sell	-158,001	Closed	-$1.39M	–	108
2025 Q3	$1.39M	Sell	158,001 -571,300	-78%	-$5.04M	0.07%	77
2025 Q2	$5.09M	Hold	729,301	–	–	0.34%	53
2025 Q1	$7.95M	Hold	729,301	–	–	0.57%	43
2024 Q4	$7.29M	Hold	729,301	–	–	0.46%	48
2024 Q3	$12M	Hold	729,301	–	–	0.93%	36
2024 Q2	$8.1M	Hold	729,301	–	–	0.71%	45
2024 Q1	$9.63M	Buy	729,301 +699,301	+2,331%	+$9.09M	0.71%	41
2023 Q4	$450K	Hold	30,000	–	–	0.05%	68
2023 Q3	$441K	Hold	30,000	–	–	0.04%	90
2023 Q2	$753K	Hold	30,000	–	–	0.08%	89
2023 Q1	$447K	Buy	+30,000	New	+$557K	0.05%	75
2022 Q4	–	Sell	-24,000	Closed	-$758K	–	79
2022 Q3	$758K	Hold	24,000	–	–	0.1%	72
2022 Q2	$833K	Hold	24,000	–	–	0.13%	70
2022 Q1	$2.71M	Buy	24,000 +6,500	+37%	+$752K	0.35%	50
2021 Q4	$1.68M	Buy	+17,500	New	+$1.58M	0.17%	55

Other funds holding IMUX

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

LCM

Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

PBM

Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return

Soleus Capital Management's IMUX Position: Q1 2026 in Review

Soleus Capital Management opened a new position in Immunic (IMUX) in Q1 2026: 450,000 shares worth $5M. The stake represents 0.2% of the portfolio and ranks #65 among its holdings. This is a return to the name: Soleus Capital Management previously reported a position in IMUX as recently as Q3 2025.

Soleus Capital Management first reported a position in IMUX in Q4 2021 and has held it in 16 quarters since. The position peaked at $12M in Q3 2024. 75 funds tracked by Wall St. Rank hold IMUX as of Q1 2026.

Soleus Capital Management held 450,000 shares of Immunic worth $5M as of Q1 2026.
Immunic was a new Soleus Capital Management position in Q1 2026.
Immunic made up 0.2% of Soleus Capital Management's portfolio in Q1 2026, its #65 holding.
Soleus Capital Management first reported a position in Immunic in Q4 2021 and has held it in 16 quarters since.
Soleus Capital Management's Immunic position peaked at $12M in Q3 2024.
75 funds tracked by Wall St. Rank held Immunic as of Q1 2026.

Based on Soleus Capital Management's 13F filing for Q1 2026, filed 14 May 2026.